What is the recommended intravenous aztreonam dosing for adults and children, including adjustments for infection severity and renal impairment?

Aztreonam Dosing Recommendations

For adults with normal renal function, administer aztreonam 1-2 g intravenously every 6-8 hours, with 2 g every 6-8 hours recommended for severe or life-threatening infections, particularly those caused by Pseudomonas aeruginosa. 1

Adult Dosing by Infection Severity

The FDA-approved dosing varies based on infection type and severity 1:

• Urinary tract infections: 500 mg to 1 g every 8-12 hours
• Moderately severe systemic infections: 1-2 g every 8-12 hours
• Severe systemic or life-threatening infections: 2 g every 6-8 hours
• Maximum daily dose: 8 g per day

For Pseudomonas aeruginosa infections specifically, use 2 g every 6-8 hours at initiation of therapy due to the serious nature of these infections. 1 The intravenous route is mandatory for patients requiring single doses >1 g or those with bacterial septicemia, localized parenchymal abscess, peritonitis, or other severe systemic infections. 1

Guidelines for complicated intra-abdominal infections support aztreonam dosing at 1-2 g every 6-8 hours. 2

Pediatric Dosing

Administer aztreonam intravenously to pediatric patients at 30 mg/kg every 6-8 hours, with the frequency determined by infection severity (maximum 120 mg/kg/day). 1

Specific pediatric dosing 2, 1:

• Mild to moderate infections: 30 mg/kg every 8 hours
• Moderate to severe infections: 30 mg/kg every 6-8 hours

For complicated intra-abdominal infections in children, guidelines recommend 90-120 mg/kg/day divided every 6-8 hours. 2 Intramuscular administration data in pediatric patients are insufficient, so the intravenous route should be used. 1

Renal Impairment Adjustments

Dose reduction is mandatory in renal impairment because aztreonam is primarily renally eliminated (60-70% excreted unchanged in urine). 1, 3

Moderate Renal Impairment (CrCl 10-30 mL/min/1.73 m²)

• Give standard loading dose (1-2 g)
• Reduce maintenance dose to 50% of usual dose at the usual interval (every 6,8, or 12 hours) 1

Severe Renal Impairment (CrCl <10 mL/min/1.73 m²)

• Give standard loading dose (500 mg, 1 g, or 2 g)
• Reduce maintenance dose to 25% of the initial dose at the usual interval 1
• For hemodialysis patients: Add one-eighth of the initial dose after each hemodialysis session 1

Population pharmacokinetic modeling confirms these adjustments achieve >90% probability of target attainment for patients with moderate and severe renal impairment. 4

Simplified Hemodialysis Dosing

For end-stage renal disease patients on hemodialysis, 1-2 g administered once daily after hemodialysis achieves adequate pharmacodynamic targets (>90% probability of target attainment up to MICs of 4-8 mg/liter, respectively). 5 This simplified approach is more practical than the complex manufacturer regimen, though thrice-weekly dosing should be avoided except in nonsevere infections with MICs ≤0.5 mg/liter. 5

Elderly Patients

Calculate creatinine clearance in elderly patients rather than relying on serum creatinine alone, as renal function is a major determinant of dosing and may be diminished despite normal serum creatinine. 1 The Cockcroft-Gault formula should be used to estimate creatinine clearance, and doses adjusted accordingly based on the renal impairment categories above. 1

Pharmacokinetic Considerations

Aztreonam has a serum half-life of approximately 1.7 hours in patients with normal renal function, with peak levels occurring immediately after IV infusion or at 1 hour after IM injection. 1, 3 The drug achieves therapeutic concentrations in multiple body fluids and tissues including bile, cerebrospinal fluid (in inflamed meninges), pleural fluid, and bone. 1

Continue therapy for at least 48 hours after the patient becomes asymptomatic or evidence of bacterial eradication is obtained. 1 Persistent infections may require several weeks of treatment. 1

Critical Pitfalls to Avoid

• Never use doses smaller than indicated - the FDA label explicitly warns against this. 1
• Do not use aztreonam as monotherapy for empiric treatment when gram-positive or anaerobic coverage is needed, as it has strictly gram-negative aerobic activity. 6
• Always adjust for renal function - failure to reduce doses in renal impairment leads to drug accumulation and prolonged serum levels. 1, 4
• Avoid intramuscular administration in pediatric patients due to insufficient safety data. 1